An observational study in Liver Cirrhosis, Viral Pneumonia and Fungal Infection, sponsored by Universitaire Ziekenhuizen KU Leuven. Active, not recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Liver Cirrhosis with a site in Belgium — 11 open to participants now, 13 under way, 2 of them phase 3. Liver Cirrhosis · Belgium.
Among the 41 studies in Liver Cirrhosis with a site in Belgium, this one is the 9th largest by planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2025, is one of 17 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 38th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →11 of the 41 studies in Liver Cirrhosis with a site in Belgium are open now. Recruiting first, the newest first:
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
University Medical Center Groningen · Sites in Belgium, Austria, Czechia and 9 more countries
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
Centre Hospitalier Universitaire Saint Pierre · Sites in Belgium
Ages 18+
Boehringer Ingelheim · Sites in Belgium, United States, Argentina and 34 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 12 · Phase 3 9 · Phase 4 2
First in 2000; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 172 across 528 observational studies indexed under Liver Cirrhosis.
Median enrollment 159 across the 24 interventional studies, 450 across the 17 observational. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 41 have an industry lead sponsor. The 10 most frequent:
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Universitaire Ziekenhuizen KU Leuven has 2 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Liver Cirrhosis with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07238114Universitaire Ziekenhuizen KU LeuvenLiver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors | 2027-07-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 41 studies in Liver Cirrhosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection of the respiratory system, caused by a specific fungus called Aspergillus species. It is already known that patients with a weakened immune system are at higher risk of developing this disease. Recently, it has also been shown that patients with viral pneumonia (such as influenza or COVID-19) and patients with liver cirrhosis who are admitted to the intensive care unit are also vulnerable to this infection.
This study aims to better define the epidemiology, clinical risk factors, outcomes, and treatment of IPA in ACLF patients admitted to the ICU. By combining clinical data with histological findings from autopsies, the study seeks to improve diagnostic accuracy, risk prediction, and timely initiation of antifungal therapy.
The study population consists of patients with known or suspected liver cirrhosis who were admitted to the Medical ICU of UZ Leuven.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study population includes patients with confirmed or suspected liver cirrhosis who were admitted to the Medical ICU of UZ Leuven. Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection, historically seen in severely immunocompromised patients. In recent years, it has also been increasingly recognized in ICU patients without classic immunosuppression, including those with viral pneumonia (e.g., influenza, COVID-19) and those with liver cirrhosis and acute-on-chronic liver failure (ACLF).
The study population consists of patients with known or suspected liver cirrhosis who were admitted to the Medical ICU of UZ Leuven.
IPA incidence
The incidence of proven invasive pulmonary aspergillosis (IPA) in critically ill cirrhotic patients will be assessed. Routinely used biochemical and microbiological tests (such as galactomannan and Aspergillus PCR) will be performed on blood and BAL samples stored in the biobank to identify affected patients.
Time frame: From the date of ICU admission until ICU discharge, approximately 7 days
Identifying whether ACLF is an independent risk factor for IPA in EORTC-negative critically ill patients
The occurrence of IPA will be compared between an ACLF EORTC-negative cohort and a non-ACLF cohort
Time frame: From the date of ICU admission until ICU discharge, approximately 7 days
Clinical characteristics of IPA
Baseline characteristics, organ failures, organ support, outcome parameters
Time frame: From the date of ICU admission until ICU discharge, approximately 7 days
Radiological characteristics of IPA
Chest CT
Time frame: From the date of ICU admission until ICU discharge, approximately 7 days
Mycological characteristics of IPA
Galactomannan testing, Aspergillus PCR, mycological culture
Time frame: From the date of ICU admission until ICU discharge, approximately 7 days
Impact of IPA on length of ICU stay
Time frame: From the date of ICU admission until ICU discharge, approximately 7 days
Impact of IPA on length of hospital stay
Time frame: From the date of ICU admission until hospital discharge, approximately 36 days
Impact of IPA on mortality
Time frame: From ICU admission until 90 days post-admission
Impact of IPA on liver transplant eligibility
Time frame: From the date of ICU admission until ICU discharge, approximately 7 days
Impact of IPA on liver transplant delisting
Time frame: From the date of ICU admission until ICU discharge, approximately 7 days
Histological characteristics of IPA using tissue staining
Histological characteristics of IPA in critically ill cirrhotic patients will be analyzed. Additional histological staining (e.g., Grocott stain) will be performed to detect fungal hyphae.
Time frame: Through study completion, an average of 3 years
Histological characteristics of IPA using microbiological testing
Histological characteristics of IPA in critically ill cirrhotic patients will be analyzed. Additional microbiological testing (e.g., Aspergillus PCR) will be performed to detect fungal hyphae.
Time frame: Through study completion, an average of 3 years
Correlation of pre-mortem data with post-mortem lung tissue findings
Time frame: Through study completion, an average of 3 years
Started Aug 2025 (actual). Primary completion is estimated for Jul 2027, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →